文献速递慢性肾脏病

醛固酮、盐皮质激素受体激活与慢性肾脏病:演变中的治疗范式综述

Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
PubMed 文献 · Am J Kidney Dis · 2022-09-01

本综述讨论盐皮质激素受体(MR)拮抗的基本科学与临床适用性,美国食品药品监督管理局(FDA)近期批准非甾体类盐皮质激素受体拮抗剂(MRA)非奈利酮用于慢性肾脏病(CKD)这一适应证。综述回顾非奈利酮相关高钾血症及减轻其风险的策略,并提出MR激活及其所致炎症和纤维化不仅是糖尿病CKD、也是非糖尿病CKD的实质性致病介质,最后简要讨论将MR拮抗扩展至更广泛非糖尿病肾脏病的近期与未来临床试验。

要点

  • MR激活参与加重肾损伤、炎症和纤维化以及CKD进展。
  • FDA近期批准非甾体类MRA非奈利酮用于CKD这一适应证。
  • 高钾血症构成实施循证MR阻断的制约因素。

核心结论

  • MR激活参与加重肾损伤、炎症和纤维化以及CKD进展;FDA近期批准非甾体类MRA非奈利酮用于这一适应证。
  • 作者提出MR激活及其所致炎症和纤维化不仅是糖尿病CKD、也是非糖尿病CKD的实质性致病介质。
  • 作者简要讨论了聚焦于将MR拮抗的特性扩展至更广泛非糖尿病肾脏病(如非白蛋白尿CKD患者)的近期与未来临床试验。

研究设计与样本

  • 综述:讨论MR拮抗的基本科学与临床适用性。
  • 综述:在非奈利酮背景下回顾MRA相关高钾血症并讨论演变中的减轻风险策略以增强该治疗的安全性和疗效。
  • 综述:提及FIDELIO-DKD和FIGARO-DKD临床试验仅聚焦于2型糖尿病患者。

主要发现

  • 多项临床研究已明确MR拮抗在减轻进展性肾脏病方面的疗效。
  • FDA近期批准非甾体类MRA非奈利酮用于CKD这一适应证。
  • 高钾血症构成实施循证MR阻断的制约因素。
  • FIDELIO-DKD和FIGARO-DKD临床试验仅聚焦于2型糖尿病患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mineralocorticoid receptor (MR) activation is involved in propagating kidney injury, inflammation, and fibrosis and in the progression of chronic kidney disease (CKD). Multiple clinical studies have defined the efficacy of MR antagonism in attenuating progressive kidney disease, and the US Food and Drug Administration recently approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone for this indication. In this review, we consider the basic science and clinical applicability of MR antagonism. Because hyperkalemia constitutes a constraint to implementing evidence-based MR blockade, we review MRA-associated hyperkalemia in the context of finerenone and discuss evolving mitigation strategies to enhance the safety and efficacy of this treatment. Although the FIDELIO-DKD and FIGARO-DKD clinical trials focused solely on patients with type 2 diabetes mellitus, we propose that MR activation and the resulting inflammation and fibrosis act as a substantive pathogenetic mediator not only in people with diabetic CKD but also in those with CKD without diabetes. We close by briefly discussing both recently initiated and future clinical trials that focus on extending the attributes of MR antagonism to a wider array of nondiabetic kidney disorders, such as patients with nonalbuminuric CKD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Epstein M, Kovesdy CP, Clase CM, et al. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms. Am J Kidney Dis. 2022. PMID: 36057467. doi:10.1053/j.ajkd.2022.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。